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Abstract 
The bioorthogonal reaction between tetrazines and trans-cyclooctenes is a method for the rapid 
construction of F-18 probes for PET imaging. Described here is a second generation 18F-labeling 
system based on a conformationally strained trans-cyclooctene (sTCO)—a dienophile that is 
approximately 2 orders of magnitude more reactive than conventional TCO dienophiles. Starting 
from a readily prepared tosylate precursor, an 18F labeled sTCO derivative (18F-sTCO) could be 
synthesized in 29.3 +/- 5.1% isolated yield and with high specific activity. Tetrazine ligation was 
carried out with a cyclic RGD-conjugate of a diphenyl-s-tetrazine analogue (RGD-Tz) chosen from 
a diene class with an excellent combination of fast reactivity and stability both for the diene as well 
as the Diels-Alder adduct. For both the tetrazine and the sTCO, mini-PEG spacers were included 
to enhance solubility and improve the in vivo distribution profile of the resulting probe. Extremely 
fast reactivity (up to 2.86 x 105 M-1s-1 at 25 °C in water) has been observed in kinetic studies in the 
reaction of sTCO with diphenyl-s-tetrazine derivatives. A kinetic study on sTCO diastereomers in 
55:45 MeOH:water showed that the syn-diastereomer displayed slightly faster reactivity than the 
anti-diastereomer. An 18F-sTCO conjugate with RGD-Tz demonstrated prominent and persistent 
tumor uptake in vivo with good tumor-to-background contrast. Unlike most radiolabeled RGD 
peptides, the tumor uptake of this PET agent increased from 5.3 +/- 0.2% ID/g at 1 h post injection 
(p.i.), to 8.9 +/- 0.5% ID/g at 4 h p.i., providing evidence for prolonged blood circulation. These 
findings suggest that tetrazine ligations employing 18F-sTCO should serve as a powerful and general 
platform for the rapid construction of peptide or protein derived PET agents. 
Key words: bioorthogonal reaction, strained trans-cyclooctene (sTCO), positron emission tomography (PET), 
18F, RGD peptide. 
Introduction 
Positron emission tomography (PET) is a 
non-invasive imaging modality with the capacity to 
track radiolabeled biomolecules in vivo. This imaging 
technique employs radionuclides that emit positrons 
that collide with electrons and result in two detectable 
γ-rays.[1, 2] Of the common radionuclides that are 
utilized in PET, F-18 is the most broadly utilized due 
to the high positron efficiency, high specific 
radioactivity and clinically attractive half-life (~110 
min).[3] These properties can minimize the toxic 
effects and radiation exposure to the patient. 
However, the short half-life of F-18, the modest 
nucleophilicity of fluoride, and the low concentrations 
that are intrinsic to both biology and radiochemistry 
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render it challenging to incorporate F-18 in complex 
biomolecules. The simple relationship between 
biomolecular rate constant and concentration shown 
in Table 1 illustrates the importance of fast rates to the 
field of F-18 labeling. Accordingly, there is a high 
demand for methods that efficiently introduce F-18 to 
biological macromolecules.  
 
Table 1. Illustration of the practical importance of fast, 
bimolecular reactivity for radiolabeling at 1 M. Radionuclides 
such as F-18 are prepared in small quantity and low concentration 
(typically ≤ 1 M). Proteins and other biological macromolecules 
are typically utilized at micromolar concentrations. As both 
reactants are present in low concentration, fast reaction rates are 
essential to efficient coupling. The bioorthogonality and fast rate of 
the tetrazine-TCO ligation make it unusually well suited for 
radiolabeling applications.  
 
 
 
 
The field of bioorthogonal chemistry is having a 
transformative influence on diverse fields including 
chemical biology, materials science, and nuclear 
medicine.[4-12] Since it was first introduced by us and 
others in 2008,[13-15] the tetrazine ligation has had a 
growing impact in biomedical research including 
radiolabeling, pretargeted imaging, in vivo reactions 
and other applications.[16-22] Our group has shown 
that the bioorthogonal reactions of tetrazines with 
trans-cyclooctene dienophiles proceed with 
exceptionally fast reaction rates (Figure 1).[23] The 
tetrazine-trans-cyclooctene ligation has become an 
important tool for biomolecular labeling because it is 
more rapid than other classes of bioorthogonal 
reactions.[24] Especially rapid reactivity has been 
observed for the conformationally strained 
dienophile, (1R,8S,E)-bicyclo[6.1.0]non-4-en-9-ylme-
thanol (sTCO),[25] for which rate constants as fast as 
3.3 x 106 M-1s-1 have been measured (Figure 1c).[26] By 
comparison, strain driven reactions of azides with 
cyclooctynes typically proceed with rates constants < 
1 M-1s-1.[24] Speed of labeling is a premium 
consideration for radiolabeling biological molecules, 
as both the radiolabel and the biomolecule are 
typically low in concentration. Recently, intracellular 
labeling of HaloTag fusion proteins has been used to 
compare the efficiency of bioorthogonal reactions 
involving tetrazine or azides with cyclopropenes, 
norbornenes, cycloalkenes and trans-cycloalkenes[10] 
In these studies, trans-cycloalkenes were identified as 
unique labeling reagents with sTCO-based reagents 
displaying the fastest reactivity. Moreover, while 
fluorescent reporters based on bicyclononyne (BCN) 
were prone to off-target labeling, TCO-based 
reporters were much more selective.[10] To date, 
radiolabeled analogs of sTCO have not yet been 
described. 
 
 
Figure 1. The tetrazine ligation with trans-cyclooctenes serves as a rapid method for 
the assembly of biomolecular-probe constructs. (A) The first generation system for 
F-18 labeling proceeds with fast kinetics but the Diels-Alder conjugate displays poor 
metabolic stability. (B) Diels-Alder conjugate from 1 and diphenyl-s-tetrazine 
derivative 3 displays improved metabolic stability. (C) The conformationally strained 
sTCO is the most reactive dienophile described to date, with rate constants of up to 
3.3. x 106 M–1s–1 for room temperature conjugations in water. 
 
In recent years several radiolabeled 
trans-cyclooctenes and s-tetrazines have been 
developed for applications in rapid radiolabeling. 
Previously we described an F-18 radiolabeling 
method that utilizes functionalized derivatives of 
di-2-pyridyl-s-tetrazine (2) and an 18F-labeled 
trans-cyclooctene (1) (Figure 1a).[23, 27-30] Analogs of 
these compounds have been shown to combine with 
rapid kinetics,[26] thereby enabling probe 
construction for cancer imaging and diabetes 
monitoring within seconds.[28, 30] More recently, we 
have explored the probe 3 derived from 
diphenyl-s-tetrazine, which is less rapid but gives 
Diels-Alder adducts with improved in vivo stability 
relative to the first generation system.[29] 18F-labeled 
trans-cyclooctene 1 has also been investigated for 
pretargeted PET imaging in the brain.[31]  
 To great effect, Robillard and coworkers have 
used the trans-cyclooctene/di-2-pyridyl-s-tetrazine 
system for pretargeted cancer imaging. In this case 
trans-cyclooctene was used as a tagging compound 
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while a DOTA modified tetrazine moiety was used to 
attach either 111In or 177Lu radiolabels.[20, 21, 32-34] 
Weissleder and coworkers have shown that polymer 
modified tetrazines can be used for in vivo 
bioorthogonal labeling and PET imaging using 
18F-labeled TCO 1.[17] Weissleder, Lewis and 
coworkers reported a pretargeting approach for PET 
imaging based on this method and demonstrated 
dramatically reduced non-targeted organ uptake.[22] 
Spivey and coworkers used a 68Ga-DOTA modified 
3-methyl-6-phenyl-s-tetrazine to construct probes 
from norbornene-labeled compounds.[35] In 2014, 
Devaraj and coworkers demonstrated that tetrazine 
modified, 64Ga-chelating polymers could be employed 
in a proof-of-principle experiment for pretargeted 
PET imaging of trans-cyclooctene tagged antibodies 
targeting cancer cells.[36] Zeglis et al. used tetrazine 
bearing amino acids for 89Zr labeling of peptides 
applying a trans-cyclooctene which was modified 
with deferrioxamine, a chelating agent for 
zirconium.[37]  
 While 1 was the only known 18F labeled 
trans-cyclooctene, there have been considerable efforts 
recently to produce 18F-labeled tetrazines. In 2014, 
Kuntner, Mikula and coworkers described a practical 
synthesis of an 18F-labeled s-tetrazine.[38] While this 
dialkyl-s-tetrazine showed lower reactivity than 
commonly used tetrazines, direct F-18 labeling was 
possible and the compound exhibit good 
pharmacokinetic properties as well as high in vivo 
stability.[38] More recently, an 18F-labeled 3-chloro-6- 
benzyloxy-s-tetrazine was described,[39] and 
Weissleder, Ploegh and coworkers introduced an 18F 
labeled tetrazine based on 18F-2-deoxyfluoroglucose, 
linked to a methyl-phenyl-s-tetrazine by oxime 
ligation, which enabled rapid radiolabeling of a 
trans-cyclooctene labeled peptide.[40] Ploegh, Liang 
and coworkers also introduced an 18F labeled 
SFB-tetrazine and successfully construct PET probes 
with trans-cyclooctene tagged antibody fragment.[41] 
Lewis and coworkers introduced another 18F-tetrazine 
in 2015, which was radiolabeled by an aluminum- 
[18F]fluoride-NOTA-complex and successfully 
applied in pretargeted PET imaging of pancreatic 
cancer xenografts using a trans-cyclooctene labeled 
antibody.[42] A dipyridyl-s-tetrazine labeled by 11C 
was recently introduced by Herth and coworkers.[43]  
While there has been a surge in recent activity 
directed toward the development of new 18F-labeled 
tetrazines, we recognized that the fastest reactivity 
would be borne out with conformationally strained 
sTCO derivatives. Accordingly, we sought to develop 
an 18F labeled trans-cyclooctene that would display 
superior kinetics in tetrazine ligation. Here, we 
describe 18F-sTCO—a new radiotracer based on the 
most reactive trans-cyclooctene dienophile. It is 
shown that 18F-sTCO rapidly combines with 
tetrazines and can be used to rapidly assemble probes 
for PET imaging. The kinetics in Diels-Alder reactions 
of the two diastereomers of sTCO were evaluated, and 
the more reactive syn-sTCO diastereomer was utilized 
for further study in PET probe construction. The 
tetrazine ligation with 18F-sTCO was used to 
synthesize a radiolabeled RGD peptide and in a 
mouse tumor model was demonstrated to have a high 
level of tumor uptake relative to that in liver, kidney, 
and muscles. After 4 h post injection, the tumor was 
the most prominent image in the PET scan with tumor 
uptake that was 1.6–2.4 fold higher than other major 
organs. 
Materials and methods 
All commercially available analytical grade 
chemical reagents were purchased from Aldrich (St. 
Louis, MO) and used without further purification. 
Analytical reversed-phase HPLC using a Gemini 5μ 
C18 column (250 x 4.6mm) was performed on a 
SPD-M30A photodiode array detector (Shimadzu) 
and model 105S single-channel radiation detector 
(Carroll & Ramsey Associates). Radio HPLC analyses 
were carried out at 1 mL/min with water/acetonitrile 
eluent mixtures. For other HPLC analyses, the 
solvents were modified with 0.1% TFA.  
Chemistry 
Synthetic protocols, characterization details, and 
copies of 1H NMR, 13C NMR, and 19F NMR spectra, 
the crude HPLC trace for 18F labeling, and the HPLC 
data for the PBS stability study can be found in the 
Supplementary Material. 
Stopped-Flow Kinetic Analysis 
The second order rate constant was measured 
under pseudo-first order conditions using an excess of 
the appropriate sTCO diastereomer (4 or 5), and by 
following the exponential decay of absorbance due to 
the tetrazine chromophore of 11 at 298 nm using an 
SX 18MV-R stopped-flow spectrophotometer 
(Applied Photophysics Ltd.). For each run, equal 
volumes of 45:55 water:methanol solutions of sTCO 
and PEGylated tetrazine 11 were mixed in the 
stopped flow device. Reactions were carried out with 
tetrazine 11 at 0.05 mM and final concentrations of 
0.245, 0.49, 0.98 and 1.47 mM for the syn-diastereomer 
5. Similarly, reactions were carried out with tetrazine 
11 at 0.05 mM and final concentrations of 0.25, 0.50, 
1.00 and 1.50 mM for the anti-diastereomer 4. A total 
of 400 data points were recorded over a period of 1 
second, and each sample was performed in 
sextuplicate at 298 K. The kobs was determined by 
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nonlinear regression analysis of the data points using 
Prism software (v. 6.00, GraphPad Software Inc.). The 
results are reported in the Supporting Information. 
Radiochemistry 
The radiolabeling reactions were carried out 
using the following protocol unless specified. 
sTCO-tosylate 8 (9.1 μmol) was dissolved in MeCN 
(30 μL) and then allowed to react with 18F-TBAF (200 
mCi) at 85 °C for 10 min. The reaction was quenched 
by adding water (500 μL). The mixture was then 
passed through a Sep-Pak cartridge (Sep-Pak Plus 
light alumina) followed by HPLC purification. After 
HPLC purification, the fraction containing the desired 
product was diluted with 10 mL of water, trapped on 
C18 Sep-Pak, washed with 10 mL water, and eluted 
off with 0.5 mL EtOH. A portion of the solution 
containing 18F-9 was reserved for the in vitro stability 
test. Then a fraction of the solution (10 mCi, estimated 
to be 4.8 nmol) was mixed with a DMSO solution of 
tetrazine-RGD conjugate 12 (ranging from 0.07 μmol 
to 3.3 nmol). After shaking for 10 seconds at room 
temperature, a portion of the reaction mixture (3 mCi) 
was loaded onto HPLC for further analysis. The 
HPLC eluent containing 18F-15 was collected and 
organic solvent was removed using rotary evaporator. 
After carefully adjusting the pH to 7.5, 18F-15 was 
reconstituted in 1x PBS for the stability test and small 
animal studies.  
In Vitro Stability 
18F-9 and 18F-15 was incubated in 1x PBS buffer at 
37 °C. An aliquot of the solution (~25 μCi) was taken 
out and loaded on HPLC at 1 h and 2 h time point for 
analysis. 18F-9 was also incubated in FBS at 37 °C and 
after 1 h, an aliquot of the solution (~25 μCi) was 
taken out and added to an equal volume of TFA. 
Similarly,18F-15 was also incubated in FBS at 37 °C, 
and at 2 and 4 h time points, aliquots of the solution 
(~25 μCi) were taken and added to an equal volume of 
TFA. For each sample, the mixture was centrifuged at 
14000 rpm for 5 min. The supernatant was then 
diluted with 1 mL water and loaded on C18 Sep-Pak. 
After washing with 1 mL water, the cartridge was 
eluted with 0.5 mL acetonitrile. The water fraction and 
acetonitrile fraction were combined and loaded on 
HPLC for analysis  
Small Animal PET Imaging 
Animal procedures were performed according to 
a protocol approved by the UNC Institutional Animal 
Care and Use Committee. PET scans and image 
analysis were performed using a small animal PET 
scanner as previously reported.[44] Human U87MG 
tumor-bearing mice were anesthetized using 2% 
isoflurane and injected with 3.7 MBq (100 μCi) of 
18F-15 via the tail vein. At 0.5, 1.0, 2.0, and 4.0 h post 
injection, static emission scans were acquired for 10 
min. Normal nude mice were injected with 3.7 MBq 
(100 μCi) of 18F-sTCO-PEG-tetrazine (compound 
obtained by combining 18F-9 and 11) or 18F-9 using the 
same protocol. Raw PET images were reconstructed 
using 2D ordered subset expectation maximization 
(OSEM) algorithm. No background correction was 
performed. Regions of interest (ROI) were manually 
drawn over the tumor and other organs on the decay 
corrected coronal images. Based on the assumption 
that the tissue density is 1 g/mL, the ROIs were 
converted to % ID/g by dividing dose per gram at 
ROI by injected dose.  
Statistical analysis 
Quantitative data were expressed as 
mean ± SD. Means were compared using 
one-way ANOVA and Student’s t test. P 
values <0.05 were considered statistically 
significant. 
Results and Discussion 
Chemistry  
The anti-diastereomer of sTCO (4) 
was prepared as described previously, and 
the syn-diastereomer 5 was prepared as 
shown in Figure 2A. Thus, photoisomeri-
zation of 7 using our previously described 
flow reactor [14] gave syn-sTCO 5 in 81% 
yield. Our initial efforts to activate 
syn-sTCO 5 through reaction with NsCl or 
TsCl were unsuccessful, and lead only to 
skeletal rearrangement products. After 
 
 
Figure 2. (A) Synthesis of syn-sTCO 5, labeling precursor 8, cold standard 19F-9, and radiotracer 
18F-9. (B) Synthesis of a cyclic RGD-diphenyl-s-tetrazine conjugate 12. 
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experimentation, we developed a synthesis that 
directly provided a tosylate product through 
alkylation of the alcohol 5 with a bis-tosylate that 
contained a mini-PEG linker. Thus, combination of 
this alcohol with KH and triethylene glycol ditosylate 
gave the sTCO tosylate 8 in 28% yield. To create the 
HPLC standard, the treatment of 8 with TBAF in 
anhydrous THF gave the 19F-labeled derivative 9 in 
76% yield. A diphenyl-s-tetrazine conjugate of a cyclic 
RGD was synthesized as shown Figure 2B. The 
nitrophenylcarbonate 10 was sequentially coupled 
with a “mini-PEG” amino acid to give 11. Subsequent 
coupling with NHS and conjugation with the cyclic 
peptide RGDyK gave 12 in high yield. 
 
 
Figure 3. Rapid reactions of s-TCO derivatives with tetrazines. (A) Rate constants of 
anti-sTCO and tetrazine analogs in water. (B,C) Rate constants for the syn- and anti- 
diastereomers of sTCO were measured in mixed aqueous/organic media. (B) Kinetic 
data for the reaction of 5 (0.49 mM) and 11 (0.05 mM). The sTCO syn-diastereomer 
5 is slightly more reactive than the anti-diastereomer 4.  
 
Stopped flow kinetic analysis was used to 
measure the rate of the Diels-Alder reaction between 
tetrazine derivative 11 and anti- and 
syn-diastereomers of sTCO (4 and 5, respectively). In a 
prior study with 13, a mini-PEG derivative of the 
sTCO anti-diastereomer, it was found that the water 
soluble diphenyl-s-tetrazine analog 14 and the 
di-2-pyridyl-s-tetrazine analog 16 react with rate 
constants of 2.86 x 105 M–1s–1 and 3.3 x 106 M–1s–1 
(Figure 3a). The latter is the fastest rate constant that 
has been described for a bioorthogonal reaction. For 
the present study, we used stopped flow analysis to 
compare the relative rate of the syn- and 
anti-diastereomers of sTCO with tetrazine 11 in mixed 
organic/aqueous media (55:45 MeOH:water at 25 °C). 
As expected, the rates in MeOH:water were ~9 fold 
slower than the measurements made in purely 
aqueous media, but still extremely rapid. The rate 
constant for the syn-diastereomer 5 with tetrazine 11 
was k2 3.7 x 104 (+/– 0.1 x 103) M–1s–1, and the 
anti-diastereomer 4 reacted with a rate constant k2 3.3 
x 104 (+/– 0.1 x 103) M–1s–1. Because the 
syn-diastereomer was more reactive it was chosen for 
further development in PET probe construction.  
Radiochemistry 
18F-labeled sTCO (18F-9) was produced using the 
protocol described in Figure 2. By treating tosylate 
precursor 8 (182 mM) with 18F-TBAF in acetonitrile at 
85 °C for 10 min, we were able to obtain the 
radiolabeled 18F-9 in 29.3 +/– 5.1% isolated 
radiochemical yield with 99% radiochemical purity 
after HPLC purification (Figure 2a, Figure 5a). Here, 
the reaction concentration was determined to be 
important, as running the reaction at 91 mM gave 
18F-9 in only 9.3 +/– 2.4% isolated yield. The specific 
activity was determined to be 2.1 +/- 0.8 Ci/µmol. 
The product identity was confirmed by co-injection 
with an independently synthesized 19F-9 standard. 
Prior to reacting with targeting molecules, we first 
tested the in vitro stability of 18F-9. After incubation in 
1X PBS, the radiopurity remained at 97.5% and 97.3% 
at 1 hour and 2 hour time points, respectively (Figure 
S3). This result demonstrated that 18F-9 is sufficiently 
stable to construct PET probes in aqueous solution. It 
was also observed that 18F-9 was stable in fetal bovine 
serum for 1 hour with retention of 74% radiochemical 
purity (Figure S10).  
As depicted in Figure 4, the conjugation of 18F-9 
with RGD-tetrazine 12 (700 µM) produced conjugate 
18F-15 as a mixture of isomers. The starting material 
18F-9 was completely consumed upon initial assay (<5 
minutes). Reducing the concentration of 12 to 33 µM 
lead to an inversion in stoichiometry, and the 
complete consumption of 12 and the observation of 
unreacted 18F-9. This ability to achieve complete 
labeling when the 18F-labeled substrate is used in 
excess speaks to the high efficiency and rate of 
bioorthgonal reaction using 18F-9. 
 Under ambient reaction conditions, a 91% 
radiochemical yield of 18F-15 was obtained with 99% 
purity (Figure S4) after HPLC purification. The crude 
radio-HPLC trace is displayed in Figure 5B. The 
specific activity was determined to be 0.91 +/- 0.20 
Ci/µmol. An analog reaction with 19F-9 produced the 
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isomeric “cold” Diels-Alder conjugates 19F-15. LC-MS 
analysis confirmed that the both of the major peaks 
from the conjugation had mass spectra matching the 
theoretical for 19F-15 (Supporting Information). More 
rapidly eluting minor peaks also had correct mass 
data, and likely correspond to the aminal (hydrated) 
forms of the product.[25] The slowest eluting peak 
from the radio-HPLC trace of 18F-15 was collected and 
the in vitro stability was studied. It was observed that 
the adduct was stable in PBS buffer for 2 hours with 
retention of 98.5% radiochemical purity (Figure 5C). 
Conjugate 18F-15 was also found to be stable in fetal 
bovine serum with 96.7% and 94.5% purity at 2 and 4 
hours post incubation respectively. (Figure S10) 
 
 
Figure 4. Conjugation of 18F-9 with RGD-tetrazine 12 to produce conjugate 18F-15 
as a mixture of isomers. Cold standards were independently prepared.  
 
 Due to the low concentration and short time 
scale that is intrinsic to 18F labeling of proteins, the fast 
kinetics and bioorthogonality of the tetrazine-TCO 
ligation provide a clear benefit over conventional 
radiolabeling methods. With our prior system, highly 
reactive tetrazines were required in order to obtain 
rapid reactivity at micromolar concentrations, but the 
resulting Diels-Alder conjugates had only moderate 
stability in vivo (Figure 1a).[30]The superior reactivity 
of 18F-sTCO allows rapid kinetics (>104 M–1s–1) to be 
realized with more stable diphenyl-s-tetrazines, 
giving rise to Diels-Alder conjugates which are 
known to possess improved in vivo stability.[29] 
Moreover, the system described here leads to 
conjugates with improved blood circulation and 
higher levels of tumor uptake than observed using the 
previously described systems shown in Figure 1. 
Small Animal PET imaging 
The localization of 18F-15 in human U87MG 
tumor-bearing mice (n=5) was performed by static 
microPET scans at multiple time-point post tail vein 
injection. Selected decay-corrected coronal images at 
different time points are shown in Figure 6 after 
injection of 3.7 MBq (100 µCi) of 18F-15. High and 
persistent tumor accumulation was observed with 
good tumor to background contrast as early as 30 min 
post injection. The 2D maximum intensity projection 
for the images displayed in Figure 6 and S9. The 
quantitative biodistribution derived from 
small-animal PET images are shown in Figure 7. The 
inclusion of mini-PEG spacers resulted in a 
biodistribution profile that was significantly 
improved relative to previously constructed 
TCO/tetrazine-based probes that lack a PEG spacer, 
and the blood circulation of this new construct was 
improved significantly compared with previously 
described constructs. The tumor uptake was 5.3 +/- 
0.2, 6.9 +/- 0.5, 7.5 +/- 0.8 and 8.9 +/- 0.5 % ID/g at 
0.5, 1.0, 2.0, and 4.0 h post injection, respectively. At 
4.0 h post injection, the tumor became the brightest 
spot in PET scan, with a tumor-to-liver and 
tumor-to-kidney ratio of 1.6 and 2.4, respectively. 
Given the improved blood circulation and high levels 
of tumor uptake for this small peptide-based probe, 
we anticipate that 18F-sTCO based probes should find 
broad utility for the labeling of larger peptides, 
proteins and other biomolecules. 
 
 
 
Figure 5. Radio-HPLC analyses. (A) Purified 18F-9 after incubation in PBS for 2 h at 
37 °C. (B) Combination of 18F-9 with 12 gives two major isomeric adducts 18F-15. 
(C) The slow eluting isomer of 18F-15 after purified by HPLC, incubation in PBS for 2 
h at 37 °C, and reanalysis.  
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The specificity of 18F-15 was confirmed by a 
blocking experiment in which the radiotracer was 
co-injected with an excess amount of cRGDyK. The 
RGD peptide is a well-established targeting 
molecule,[45-49] and as can be seen in Figure 6B, in 
the presence of non-radio labeled cRGDyK (200 µg), 
the tracer uptake in tumor dropped to 4.8 +/- 0.3% at 
1 h post injection. As expected the cRGDyK peptide, 
which should be readily cleared than a PEGylated 
peptide, did not completely block the signal due to 
19F-15. However, the signal in the presence of blocking 
cRGDyK was significantly (P<0.05) lower than that 
observed without a blocking agent.  
We also performed microPET imaging with a 
normal (non-tumor bearing) nude mouse that had 
been injected with 18F-9. The imaging data indicated 
that the compound was rapidly cleared by the 
gallbladder, kidney and liver within 2 hours (Figure 
S8). We also analyzed the clearance of the compound 
obtained by combining 18F-9 with 11. This Diels-Alder 
conjugate— an analog of 18F-15 that lacks the RGD 
moiety— still remained in the blood circulatory 
system after 4 hours (Figure S7). The blood uptake 
was 2.4% ID/g at 4 h post injection. Previously, we 
have described 18F-labeled RGD probes derived from 
trans-cyclooctene 1 (Figure 1). These probes which 
lack PEGylation are cleared much more rapidly.[29, 
30] These results suggested that the entire PEGylated 
Diels-Alder moiety plays a role in enhancing the 
circulation time of the probe. Future experiments will 
aim to determine the respective contributions of the 
Diels-Alder conjugate and the PEG chains as factors in 
increasing the circulation lifetime. We believe that the 
rapid clearance of 19F–9 and the long circulation 
lifetime of its PEGylated Diels-Alder conjugates may 
prove advantageous for future applications in 
pretargeted imaging, and we are currently pursuing 
these applications.  
 
Figure 6. (A) Small animal PET images of mice bearing U87 xenograft, injected with 18F-15 and imaged 0.5 h, 1.0 h, 2.0 h and 4.0 h post injection, respectively. (B) A ‘blocking’ 
experiment in which cyclic RGDyK peptide (200 µg) was injected prior to the injection of 18F-15, with imaging at 1.0 h post injection. (C) Two-dimensional maximum intensity 
projection at 4.0 h post injection of 18F-15. 
 
 
Figure 7. Tumor and major organ radioactivity accumulation quantification from a 
static scan at 0.5, 1, 2, and 4 h post injection of 18F-15 into U87MG tumor model. 
Data are expressed as average +/- SD. 
 
Conclusions 
A conformationally strained trans-cyclooctene, 
18F-sTCO (9), was prepared via a one-step 
fluorination. This new PET-tracer is based on the 
conformationally strained trans-cyclooctene 
(sTCO)—a dienophile that is approximately 2 orders 
of magnitude more reactive than conventional TCO 
dienophiles. In a model system, the rate constants for 
sTCO-diastereomers were compared, and the 
syn-diastereomer was found to be slightly more 
reactive and therefore was chosen for further 
development. The effectiveness of 9 for the 
construction of radiolabeled probes was 
demonstrated with the production of a cyclic RGD 
based probe 15. Mini-PEG groups were included in 
the design of 15 to improve both the water solubility 
and the pharmacokinetic properties of the probe. In 
tumor-bearing mice, 18F-15 demonstrated a 
significantly improved blood half-life compared with 
monomeric RGD peptide analogs. As a result, 
increased tumor uptake of 18F-15 was observed at a 
late time point. Given the exceptional kinetics of 18F-9 
and the improved tumor uptake and accumulation of 
the derived probe 18F-15, we expect that this labeling 
system will be broadly applicable for attachment of 
F-18 to a host of applications in probe construction, 
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pretargeted imaging, and treatment applications.  
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